September 16, 2026

We are pleased to see several media outlets highlighting the continued deployment of Valvosoft® at @CHU de Rouen and the potential of focused ultrasound technology for patients with severe symptomatic aortic stenosis. 
 
As one of the pioneering centers involved in the development and clinical adoption of Valvosoft®, CHU Rouen continues to advance innovative, non-invasive treatment options that may benefit selected patients who are unable or unwilling to undergo valve replacement. Valvosoft® is CE-Marked for the treatment of severe symptomatic calcific aortic stenosis in patients not recommended for immediate Transcatheter or Surgical Aortic Valve Replacement (TAVR/SAVR) or refusing such interventions. 
These articles also recognize the long-standing collaboration between CHU Rouen and Cardiawave, bringing together clinical expertise, academic research, and technological innovation to improve patient care. 🤝  
 
👏 Congratulations to Dr. @Thibaut Hémery, Prof. @Hélène Eltchaninoff, Prof. @Eric Durand and all the multidisciplinary teams involved in making this innovation available to patients. 
 
🔗 Read the articles: 
• Paris-Normandie: TAVI, Valvosoft®: CHU Rouen at the forefront of cardiology 
https://www.paris-normandie.fr/id732878/article/2026-07-15/tavi-valvosoftr-le-chu-de-rouen-en-pointe-sur-la-cardiologie 
 
• Paris-Normandie: Ultrasound technology helping reduce valve replacement procedures 
https://www.paris-normandie.fr/id732951/article/2026-07-16/au-chu-de-rouen-des-ultrasons-pour-limiter-les-operations-de-la-valve-cardiaque  
  
#Cardiawave #Valvosoft #FocusedUltrasound #AorticStenosis #StructuralHeart #Cardiology #MedTech #Innovation #Cardiology #LifetimeManagementofAorticStenosis#HeartTeam #Innovation #MedTech @RHU Stop AS 💙 #noninvasive